- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.12. | Revelation Biosciences files for secondary offering of common stock | 1 | Seeking Alpha | ||
| 11.12. | Aktie von Revelation Biosciences erreicht 52-Wochen-Tief bei 0,42 US-Dollar | 4 | Investing.com Deutsch | ||
| 11.12. | Revelation Biosciences stock hits 52-week low at $0.42 | 1 | Investing.com | ||
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 06.12. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 03.12. | Why Revelation Biosciences (REVB) Stock Is Down 38% | 6 | Benzinga.com | ||
| 03.12. | Revelation Biosciences stock hits 52-week low at $0.7 | 3 | Investing.com | ||
| 03.12. | Revelation Biosciences-Aktie erreicht 52-Wochen-Tief bei 0,7 US-Dollar | 2 | Investing.com Deutsch | ||
| 02.12. | FDA approves Revelation Biosciences' drug trial for CKD | 3 | Investing.com | ||
| 11.11. | Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket | 3 | Benzinga.com | ||
| 09.11. | Revelation Biosciences Inc expected to post a loss of $2.29 a share - Earnings Preview | 2 | Reuters | ||
| 08.11. | Revelation Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary | 1 | Reuters | ||
| 08.11. | Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 | 211 | Business Wire | SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity... ► Artikel lesen | |
| 08.11. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 08.11. | REVELATION BIOSCIENCES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 21.10. | Revelation Biosciences faces Nasdaq delisting over noncompliance | 2 | Investing.com | ||
| 21.10. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.09. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.09. | REVELATION BIOSCIENCES, INC. - 10-Q/A, Quarterly Report | - | SEC Filings | ||
| 23.09. | REVELATION BIOSCIENCES, INC. - 10-K/A, Annual Report | - | SEC Filings | ||
| 03.09. | Revelation Biosciences files for secondary offering of about 5.1M shares | 1 | Seeking Alpha |
Seite:
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative... ► Artikel lesen | |
| ARCADIA BIOSCIENCES | 5,600 | 0,00 % | Arcadia Biosciences (RKDA) Enters Into Business Combination Agreement with Roosevelt Resources in All-Stock Transaction | DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA) and Roosevelt Resources LP announced today that they have entered into a definitive securities exchange agreement which, when... ► Artikel lesen | |
| TRACON PHARMACEUTICALS | 1,410 | 0,00 % | TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces it Will Wind Down Operations | SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was... ► Artikel lesen | |
| ALZAMEND NEURO | 1,230 | -4,65 % | Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs | ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease... ► Artikel lesen | |
| ARIDIS PHARMACEUTICALS | - | - | Aridis Pharmaceuticals, Inc.: Aridis Provides Corporate Update | LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent... ► Artikel lesen | |
| QIAGEN | 43,240 | +0,05 % | Kurs von Qiagen NV steigt etwas (43,87 €) | Der Anteilsschein von Qiagen NV notiert am Donnerstag etwas fester. Zuletzt zahlten Investoren für das Wertpapier 43,87 Euro. Für das Wertpapier von Qiagen NV steht gegenwärtig ein Kursplus 0,39 Prozent... ► Artikel lesen | |
| EVOTEC | 8,500 | -4,23 % | WARBURG RESEARCH stuft Evotec auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Warburg Research hat die Einstufung für Evotec auf "Buy" mit einem Kursziel von 14 Euro belassen. Die Aktie des Wirkstoffforschers gehöre zu den "Best Ideas 2025" des Analysehauses... ► Artikel lesen | |
| POLYRIZON | 3,250 | +200,93 % | What's Going On With Polyrizon Shares Wednesday? | ||
| BIONTECH | 107,80 | -3,84 % | Laufende Fusionskontrollverfahren: BioNTech SE, Mainz; Erwerb sämtlicher Anteile an und Alleinkontrolle über Biotheus, Cayman-Inseln /KY | Datum der Anmeldung:11.12.2024Aktenzeichen:B3-142/24Unternehmen:BioNTech SE, Mainz; Erwerb sämtlicher Anteile an und Alleinkontrolle über Biotheus, Cayman-Inseln/KY;Produktmärkte:Antikörper-Wirkstoff-Konjugate... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 30,720 | -6,17 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,215 | -12,65 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 27,920 | -11,25 % | Structure Therapeutics unveils new obesity drug candidate | ||
| CG ONCOLOGY | 28,450 | -2,74 % | CG Oncology Inc.: CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | ||
| COGNITION THERAPEUTICS | 0,584 | +30,50 % | Cognition Therapeutics, Inc.: Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies | - Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy... ► Artikel lesen | |
| MODERNA | 37,205 | -4,33 % | INDEX-MONITOR: Moderna fliegt aus Nasdaq 100 - Palantir und MicroStrategy rein | NEW YORK (dpa-AFX) - Der US-Pharmakonzern und Impfstoffhersteller Moderna muss noch vor Weihnachten aus dem technologielastigen US-Aktienindex Nasdaq 100 weichen. Das teilte der Börsenbetreiber Nasdaq... ► Artikel lesen |
Das Unternehmen REVELATION BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,011 (+3,32 %) liegt der Kurs bei 0,342 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.
